During the 1990s, MSF teams made a bitter observation: we were failing to treat some of our patients suffering from infectious diseases, while in developed countries, remarkable progress was being made in the field of health. Two decades on, medicines in developing countries are still either too expensive, aren't suitable to be used in many of the contexts in which we work (for example, in hot, humid conditions or where there's a lack of electricity), or simply don't exist for the diseases we need to treat.
In 1999, we launched the Campaign for Access to Essential Medicines, now known as the Access Campaign. Its mission focuses on three areas: overcoming barriers to access to essential medicines, stimulating research and development for neglected diseases, promoting health exceptions to global trade agreements.
In 2003, MSF joined several research institutes, including the Institut Pasteur, to create the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organisation engaged in research and development of new treatments for neglected diseases.

The XDR-TB emergency will require new strategies and new tools: business as usual would be fatal

Lusikisiki celebrates 2,200 people on ARV treatment at hand-over ceremony

As Novartis challenges India's patent law, MSF warns access to medicines is under threat

Groups urge rapid review of Canada's law on generic medicines for export

Call for moratorium on trade provisions that threaten access to medicines or treatment programmes

New MSF data shows treatment of children works in resource poor settings

Even for MSF, it is far from easy to get drugs and medical supplies to Lebanon

African sleeping sickness in the DRC
